Protocol Ledger

NCT05822752 · Phase II · ACTIVE NOT RECRUITING

Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC)

Interventional Phase II clinical trial protocol NCT05822752 sponsored by AbbVie in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-09-21 Enrollment: 130 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05822752
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)130 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05822752
Protocol FieldVerified Registry Value
NCT IdentifierNCT05822752
Consolidated Lead SponsorAbbVie
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment130 participants (ACTUAL)
Registered Start Date2023-09-21
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for AbbVie across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI